Definium Therapeutics, Inc. - 8-K Filing
Definium Therapeutics announced positive topline results from the Phase 3 Emerge study of DT120 ODT (lysergide) for major depressive disorder. The primary endpoint showed an 8.1-point placebo-adjusted reduction in MADRS score at Week 6 (p<0.0001), with rapid and durable effects observed as early as Day 2 (-14.2 point difference, p<0.0001) and lasting through Week 12 (-7.3 point difference). DT120 ODT was generally well tolerated with no serious adverse events or suicidality signal. (Items: 7.01 The information furnished pursuant to this Item 7, 8.01 Item 9)
Tickers: $MNMD